<DOC>
	<DOCNO>NCT02625922</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , crossover , placebo-controlled , Phase II clinical study evaluate effect serelaxin versus placebo ( addition SoC ) release hs-cTnI , patient CHF exercise test session .</brief_summary>
	<brief_title>Study Effect Serelaxin High-sensitivity Cardiac Troponin I ( Hs-cTnI ) Release Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Male female ≥ 18 year age , body weight ≤ 160 Kg Diagnosis stable CHF : New York Heart Association ( NYHA ) functional Class II/III . Receiving guidelinerecommended treatment CHF . Left ventricular ejection fraction &lt; 45 % , obtain within last 3 month prior screen . NTproBNP &gt; 300 ng/L sinus rhythm &gt; 900 ng/L sinus rhythm ( determine locally ) . Ability exercise least 10 12 minute base investigator 's judgment . Systolic BP ≥ 125 mm Hg randomization Renal function define eGFR ≥ 25 mL/min/1.73 m^2 screening ( sMDRD formula ) . Key Dyspnea primarily due noncardiac cause . Increased risk develop hypotension vasodilator therapy accord investigator judgement . Any contraindication exercise test spirometry . Stopping spiroergometry screen accord stopping rule , unless patient reach maximum exercise capacity define carbon dioxide production/oxygen consumption ( VCO2/VO2 ) &gt; 1.05 . Change guidelinerecommended CHF treatment within 1 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Serelaxin ,</keyword>
	<keyword>Chronic heart failure ,</keyword>
	<keyword>Spiroergometry ,</keyword>
	<keyword>Troponin ,</keyword>
	<keyword>New York Heart Association ( NYHA ) functional Class II/III ,</keyword>
	<keyword>Left ventricular ejection fraction ,</keyword>
</DOC>